IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 149 filers reported holding IMMUNOVANT INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,866,144 | +89.2% | 387,240 | -6.5% | 0.00% | +100.0% |
| Q2 2023 | $7,856,312 | +30.4% | 414,144 | +6.6% | 0.00% | 0.0% |
| Q1 2023 | $6,025,123 | -12.2% | 388,467 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $6,863,109 | +303.2% | 386,654 | +26.8% | 0.00% | +100.0% |
| Q3 2022 | $1,702,000 | +42.9% | 304,975 | -0.1% | 0.00% | – |
| Q2 2022 | $1,191,000 | -27.5% | 305,132 | +2.4% | 0.00% | – |
| Q1 2022 | $1,643,000 | -33.7% | 298,115 | +2.5% | 0.00% | -100.0% |
| Q4 2021 | $2,479,000 | +5.9% | 290,932 | +8.0% | 0.00% | 0.0% |
| Q3 2021 | $2,341,000 | -33.8% | 269,378 | -19.5% | 0.00% | 0.0% |
| Q2 2021 | $3,535,000 | -33.5% | 334,436 | +0.9% | 0.00% | -50.0% |
| Q1 2021 | $5,318,000 | -62.1% | 331,487 | +9.1% | 0.00% | -66.7% |
| Q4 2020 | $14,032,000 | +60.4% | 303,774 | +22.2% | 0.01% | +50.0% |
| Q3 2020 | $8,748,000 | +130.7% | 248,593 | +59.7% | 0.00% | +100.0% |
| Q2 2020 | $3,792,000 | – | 155,703 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |